While some information on these therapeutic candidates is restricted by confidentiality agreements, in the table below you will find links that offer more information about disclosed assets. We provide this information for informational purposes only.
| Partner | Asset Name | Target | Royalty Rate | |||
|---|---|---|---|---|---|---|
| Alora Pharmaceuticals | DSUVIA® | Acute pain | 15-75% | clinical trials | news | asset website |
| AVEO Oncology | ficlatuzumab (AV-299) | HGF | Low single-digit | clinical trials | news | posters, presentations |
| Day One | OJEMDA™ (tovorafenib) | pan-RAF | Mid-single-digit | clinical trials | news | posters, presentations |
| Janssen Biotech | cetrelimab (JNJ-63723283) | PD-1 | 0.75% | clinical trials | news | posters, presentations |
| Medexus | IXINITY® | Factor IX | Mid-single-digit | news | asset website | |
| Bayer (option) | Ovaprene® | contraceptive | low single-digit | clinical trials | news | posters, presentations |
| Rezolute | RZ358 | INSR | High single-digit to mid-teens | clinical trials | news | posters, presentations |
| Roche | faricimab | angiopoietin-2 and VEGF-A | 0.5% | clinical trials | news | posters, presentations |
| Takeda | mezagitamab (TAK-079) | CD-38 | 4% | clinical trials | news | posters, presentations |
| Organon | XACIATO™ | bacterial vaginal infection | high single-digit | news | asset website | |
| Zevra | MIPLYFFA™ (arimoclomol) | heat-shock protein amplifier | mid-single-digit | clinical trials | news | asset website |
| Partner | Asset Name | Target | Royalty Rate | |||
|---|---|---|---|---|---|---|
| AstraZeneca | rilvegostomig (AZ2396) | TIGIT/PD-1 | undisclosed | clinical trials | news | posters, presentations |
| Janssen Biotech | JNJ-63898081 | PSMAxCD3 | 0.75% | clinical trials | news | |
| Janssen Biotech | Undisclosed | GPRC5DxCD3 | 0.75% | |||
| Janssen Biotech | JNJ-63709178 | CD123xCD3 | 0.75% | clinical trials | news | |
| Merck | MK-4830 | ILT-4 | Low single-digit | clinical trials | news | posters, presentations |
| Novartis | iscalimab (CFZ533) | CD-40 | Mid-single-digit to low teens | clinical trials | news | posters, presentations |
| Novartis | gevokizumab (VPM087) | IL-1ß | High single-digit to mid-teens | clinical trials | news | posters, presentations |
| Novartis | NIR178 | adenosine A2A | Low single-digit | clinical trials | news | posters, presentations |
| Regeneron | vidutolimod (CMP-001) | TLR9 | High single-digit to double digit | clinical trials | news | posters, presentations |
| Partner | Asset Name | Target | Royalty Rate | |||
|---|---|---|---|---|---|---|
| Affimed | acimtamig (AFM13) | CD30/CD16A | Undisclosed | clinical trials | news | posters, presentations |
| Affimed | AFM24 | EGFR/CD16A | Undisclosed | clinical trials | news | posters, presentations |
| Agenus | INCAGN01949 | OX-40 | Mid-single-digit | clinical trials | news | |
| Compugen | COM902 | TIGIT | undisclosed | clinical trials | news | posters, presentations |
| Daré Bioscience | Sildenafil cream, 3.6% | phosphodiesterase-5 (PDE-5) inhibitor |
clinical trials | news | posters, presentations | |
| Denovo Biopharma | vosaroxin | topoisomerase II | high single-digit | clinical trials | news | posters, presentations |
| Incyte | INCAGN01876 | GITR | Mid-single-digit | clinical trials | news | |
| Incyte | INCAGN02385 | LAG-3 | Low to mid-single-digit | clinical trials | news | |
| Incyte | INCAGN02390 | TIM-3 | Low to mid-single-digit | clinical trials | news | |
| LadRx | aldoxorubicin | albumin-linked formulation of doxorubicin | low single-digit | clinical trials | news | posters, presentations |
| Molecular Templates | MT-0169 | CD-38 | 4% | clinical trials | news | posters, presentations |
| Monopar Therapeutics | MNPR-101 | uPAR | None | news | posters, presentations | |
| Palobiofarma | PBF-680 | adenosine A1 | Low single-digit | clinical trials | news | posters, presentations |
| Palobiofarma | PBF-677 | adenosine A3 | Low single-digit | clinical trials | news | posters, presentations |
| Palobiofarma | PBF-999 | adenosine A2A / Phosphodiesterase 10 (PDE-10) | Low single-digit | clinical trials | news | posters, presentations |
| Palobiofarma | PBF-1129 | adenosine A2B | Low single-digit | clinical trials | news | posters, presentations |
| Palobiofarma | PBF-1650 | adenosine A3 | Low single-digit | clinical trials | news | posters, presentations |
| Resilience | NTM-1632 | Botulinum neurotoxins | 15% | clinical trials | news | posters, presentations |
| Resilience | NTM-1633 | Botulinum neurotoxins | 15% | clinical trials | news | posters, presentations |
| Resilience | NTM-1634 | Botulinum neurotoxins | 15% | clinical trials | news | posters, presentations |
| Resilience | NTM-1631 | Botulinum neurotoxins | 15% | clinical trials | news | posters, presentations |
| Rezolute | AB101 | Injectable basal insulin | Low single-digit | news | posters, presentations | |
| Rezolute | RZ402 | Kallikrein inhibitor | Low single-digit | clinical trials | news | posters, presentations |
All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.
